Results 131 to 140 of about 832,259 (254)

3D videos of PET imaging with CAR NK cells

3D videos of PET/CT imaging with CAR NK ...
elisha verhaar (18055912)
core   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam, M Figura, J Heyer, S Lieber, M Huber, KL Loveland, HC Schuppe, Daniela Fietz   +7 more
wiley   +1 more source

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick, Margaretha A. Skowron, Gereon Poschmann, Patrick Petzsch, Ann Kathrin Bergmann, Kai Stühler, Jochen Hecht, Daniel Nettersheim   +7 more
wiley   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

Human CD3 complex is required for the generation of T-cell receptor-like chimeric antigen receptor targeting WT1 in natural killer cells

Cancer Immunology, Immunotherapy
Chimeric antigen receptor-natural killer (CAR-NK) cells represent a promising cellular immunotherapy platform for various cancers, offering a favorable clinical safety profile and potential to generate off-the-shelf products. However, broader application
Sudjit Luanpitpong, Jirarat Poohadsuan, Parinya Samart, Xing Kang, Ponthip Pratumkaew, Montira Janan, Surapol Issaragrisil   +6 more
doaj   +1 more source

Advances in the manufacturing of CAR-NK cells for cancer immunotherapy

6381Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have emerged as a promising new frontier in cancer immunotherapy. Building on the successes of CAR-T cell therapies, CAR-NK cells offer several potential advantages that make them ...
Schmiedel, Dominik, Dünkel, Anna, Uhlig, Julia, Tretbar, Sandy   +3 more
core   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

CAR-NK cells derived from cord blood originate mainly from CD56−CD7+CD34−HLA-DR−Lin− NK progenitor cells

Cord blood (CB)-derived chimeric antigen receptor (CAR)-natural killer (NK) cells targeting CD19 have been shown to be effective against B cell malignancies.
Shunya Ikeda, Daisuke Okuzaki, Tomoaki Ueda, Moto Yaga, Makiko Suga, Michiko Ichii, Chihaya Imai, Akihisa Hino, Kumi Shibata, Shuhei Kida, Yasutaka Ueda, Kazuhito Tsutsumi, Jiro Fujita, Atsushi Kumanogoh, Naoki Hosen, Tansri Wibowo, Yosuke Kogue, Mana Tachikawa, Shinsuke Kusakabe, Kentaro Fukushima, Hisashi Kato, Hiraku Murakami   +21 more
core   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source